- Home
- ADMA
ADMA
ADMA Biologics Inc
as 12-26-2024 12:30pm EST
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RAMSEY |
| Market Cap: | 4.1B | IPO Year: | N/A |
| Target Price: | $21.25 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.27 - $23.64 | Next Earning Date: | 11-07-2024 |
| Revenue: | $382,809,000 | Revenue Growth: | 63.39% |
| Revenue Growth (this year): | 66.84% | Revenue Growth (next year): | 14.72% |
Stock Insider Trading Activity of ADMA Biologics Inc (ADMA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Grossman Adam S | ADMA | President and CEO | Nov 22 '24 | Sell | $21.10 | 48,967 | $1,033,203.70 | 1,989,007 | |
| Tade Brad L. | ADMA | CFO and Treasurer | Nov 22 '24 | Sell | $21.15 | 15,000 | $317,250.00 | 199,433 |
Latest ADMA Biologics Inc News
ADMA Breaking Stock News: Dive into ADMA Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
Argus Research
3 days ago
ADMA: Lowering target price to $23.00
MT Newswires
6 days ago
ADMA Biologics Repays $30 Million of Term Loan Facility
GlobeNewswire
6 days ago
ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Zacks
6 days ago
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
Zacks
7 days ago
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Argus Research
9 days ago
ADMA: Lowering target price to $24.00
Zacks
13 days ago
Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year?
Compare ADMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADMA ADMA Biologics Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.